2021
DOI: 10.1016/s0140-6736(21)00188-4
|View full text |Cite
|
Sign up to set email alerts
|

SARS-CoV-2 serosurveys in low-income and middle-income countries

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
10
0

Year Published

2021
2021
2023
2023

Publication Types

Select...
6
1

Relationship

0
7

Authors

Journals

citations
Cited by 11 publications
(10 citation statements)
references
References 18 publications
(17 reference statements)
0
10
0
Order By: Relevance
“… 23 Serosurveillance studies and efforts have also been reported in some African countries e.g Nigeria, 24 , 25 Côte d’Ivoire, 23 South Africa, 26 , 27 Kenya, 28 , 29 Ethopia, 30 and other sub-Saharan African countries. 31 , 32 …”
Section: Resultsmentioning
confidence: 99%
See 1 more Smart Citation
“… 23 Serosurveillance studies and efforts have also been reported in some African countries e.g Nigeria, 24 , 25 Côte d’Ivoire, 23 South Africa, 26 , 27 Kenya, 28 , 29 Ethopia, 30 and other sub-Saharan African countries. 31 , 32 …”
Section: Resultsmentioning
confidence: 99%
“…23 Serosurveillance studies and efforts have also been reported in some African countries e.g Nigeria, 24,25 Côte d'Ivoire, 23 South Africa, 26,27 Kenya, 28,29 Ethopia, 30 and other sub-Saharan African countries. 31,32 Mortality surveillance: involves reporting and monitoring the number of COVID-19 deaths in the community, hospitals including long-term facilities, and other sites. 33 In the context of COVID-19, the number of deaths must be recorded daily or within a week.…”
Section: Category Of Covid-19 Surveillance Systemsmentioning
confidence: 99%
“…In the current scenario, in which the lack of vaccine doses has persuaded several countries to introduce different policies for individuals who had a history of SARS-CoV-2 infection (a decision that has not been fully endorsed by WHO) ( 3 ), access to reliable data about the serological status of individuals could gain new importance ( 4 ). However, whereas serological mass screening in high-income countries could be feasible using automatic, high-throughput technologies ( 5 , 6 ), this may not be a practical option in several challenging diagnostic settings where the prevalence of SARS-CoV-2 infection is still widely unknown ( 7 ). In these countries, lateral flow assays (LFAs) for the identification of SARS-CoV-2 antibodies may represent an affordable and practical tool to perform epidemiological evaluations, but only a few serological surveys have been conducted to date employing LFAs, associated or not with enzyme-linked immunosorbent assays (ELISA) ( 8 , 9 ).…”
Section: Introductionmentioning
confidence: 99%
“… 45 However, in the ongoing COVID-19 outbreak, most countries are unable to meet up with the massive diagnostic testing order given by WHO. 79 , 83 , 86 This has resulted in a continuous spread due to community transmission. 79 , 86 …”
Section: Introductionmentioning
confidence: 99%